Investigation Alert: Long-Term Investors who lost money with shares of Skye Bioscience, Inc. (NASDAQ: SKYE) should contact the Shareholders Foundation

An investigation was announced on behalf of current long-term investors in shares of Skye Bioscience, Inc. (NASDAQ: SKYE) concerning potential breaches of fiduciary duties by certain directors and officers of Skye Bioscience, Inc..

Investors who are current long term investors in Skye Bioscience, Inc. (NASDAQ: SKYE) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: SKYE stocks follows a lawsuit filed against Skye Bioscience, Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: SKYE stocks, concerns whether certain Skye Bioscience, Inc. directors are liable in connection with the allegations made in that lawsuit.

In August 2024, Skye Bioscience, Inc initiated its "CBeyond" clinical trial, a twenty-six-week, randomized, double-blind, placebo-controlled Phase 2a proof-of-concept study designed to assess nimacimab as a treatment for obesity and overweight. The CBeyond trial's primary endpoint was to demonstrate an 8% difference in mean weight loss using nimacimab versus placebo at twenty-six weeks, with a thirteen-week follow-up.
At all relevant times while the Phase 2a Beyond trial was ongoing, Skye Bioscience, Inc touted nimacimab's purported "differentiated" mechanism of action and efficacy results as purportedly demonstrated in other various studies. Critically, Skye Bioscience, Inc cited to nimacimab's purportedly potent efficacy as observed in these various studies to suggest that the results of the Phase 2a CBeyond trial were likely to be favorable, while consistently touting nimacimab's overall clinical, regulatory, and commercial prospects.

Then on October 6, 2025, Skye Bioscience, Inc issued a press release "announcing the topline data from its 26-week Phase 2a CBeyondTM proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody." The press release disclosed that the "the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo" and that "preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy."

Skye Bioscience, Inc. (NASDAQ: SKYE) declined from $5.96 per share on November 08, 2024, to as low as $1.10 per share on December 02, 2025.

According to that complaint filed in the U.S. District Court for the Southern District of California the plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that nimacimab was less effective than Defendants had led investors to believe, that accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated, and that as a result, Defendants' public statements were materially false and misleading at all relevant times.

Those who purchased shares of Skye Bioscience, Inc. (NASDAQ: SKYE) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.